Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CD7 CAR-T cell therapy based on “Natural Selection” for the treatment of Relapsed or Refractory CD7-positive Hematologic Malignancies: A large cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

GZGailing ZhangMZMin ZhangNKNa Kuang

Discussion

Loading...

Member takes

Overview

Pooled cohort analysis shows promising CR rates and safety for NS7CAR-T therapy in patients with R/R CD7-positive hematologic malignancies, highlighting its potential as a treatment option.

Key Points

  • To evaluate the efficacy and safety of NS7CAR-T therapy for patients with relapsed or refractory CD7-positive hematologic malignancies.
  • Pooled analysis of data from 5 clinical trials evaluating NS7CAR-T therapy.
  • Enrolled patients with R/R CD7-positive hematologic malignancies who received NS7CAR-T cells.
  • Collected data on demographics, CAR-T cell dosing, and post-infusion outcomes.
  • The overall response rate (ORR) reached 86.3%, with an 84.5% complete remission rate.
  • Median progression-free survival (PFS) was 547.5 days and median overall survival (OS) was 567.5 days.
  • Cytokine release syndrome (CRS) occurred in 95.8% of patients, with most cases being grade 1-2.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d231https://doi.org/10.1182/blood-2025-2540
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CD7-targeted CAR-T cell therapy showed a high efficacy for 30 patients with relapsed or refractory central nervous system T-cell lymphoblastic leukemia/lymphoma2025 · 1 citations
  2. 2CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study2025
  3. 3Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies2025 · 1 citations
  4. 4Anti-CD7 CAR T-cell therapy for ultra-high-risk relapsed/refractory T-ALL/lbl: Insights into lineage switch and consolidation strategies2025
  5. 5Safety and efficacy of CD7-CAR-T cell in patients with relapsed/refractory T-lymphoblastic leukemia/lymphoma: Phase I dose-escalation/dose-expansion study.2024 · 3 citations